NCT06078202View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

ABBV-903

Tablet; oral

Trial Locations (1)

60030

Acpru /Id# 259438, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY